Unknown

Dataset Information

0

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.


ABSTRACT: We performed a retrospective study of 90 consecutive cases with inoperable carcinoma of the oesophagus treated with definitive chemoradiation at a single cancer centre between 1995 and 2002. For the last 4 years, 73 patients have received therapy according to an agreed protocol. This outpatient-based regimen involves four cycles of chemotherapy, cycles 3 and 4 given concurrently with 50 Gy external beam radiotherapy (XRT) delivered in 25 fractions over 5 weeks. Cisplatin 60 mg m(-2) day(-1) is given every 3 weeks together with continuous infusional 5-fluorouracil 300 mg m(-2) day(-1), reduced to 225 mg m(-2) day(-1) during the XRT. In all, 45 (50%) patients suffered one or more WHO grade 3/4 toxicity, grade 3 in 93% cases. Patients received more than 90% of the planned chemoradiation schedule. The median overall survival was 26 (15, >96) months, 51% (41, 64) and 26% (13, 52) surviving 2 and 5 years, respectively. Advanced stage, particularly T4 disease, was associated with a worse prognosis. Patients considered not suitable for surgery for reasons other than their disease, mainly co-morbidity, had a significantly better outcome, median survival 40 (26, >96) months, 2- and 5-year survivals 67% (54, 84) and 32% (13, 79), respectively (P<0.001). This schedule is a feasible, tolerable and effective treatment for patients with oesophageal cancer considered unsuitable for surgery.

SUBMITTER: Crosby TD 

PROVIDER: S-EPMC2395332 | BioStudies | 2004-01-01

SECONDARY ACCESSION(S): 10.1038/sj.bjc.6601461

REPOSITORIES: biostudies

Similar Datasets

2004-01-01 | S-EPMC2409551 | BioStudies
2020-01-01 | S-EPMC7305659 | BioStudies
2013-01-01 | S-EPMC3832987 | BioStudies
2012-01-01 | S-EPMC4162394 | BioStudies
2018-01-01 | S-EPMC7590532 | BioStudies
2019-01-01 | S-EPMC6563344 | BioStudies
1000-01-01 | S-EPMC4919369 | BioStudies
2019-01-01 | S-EPMC6461928 | BioStudies
2014-01-01 | S-EPMC4254850 | BioStudies
2015-01-01 | S-EPMC4474505 | BioStudies